Daniel Gold - MEI Pharma CEO and President and Director
| MEIP Stock | USD 2.81 0.01 0.36% |
CEO
Dr. Daniel P. Gold, Ph.D. is President, Chief Executive Officer, Director of MEI Pharma, Inc. From October 2009 to April 2010, Dr. Gold joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a midstage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that advanced the companys lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research since 2010.
| Age | 70 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Address | 9920 Pacific Heights Blvd., San Diego, CA, United States, 92121 |
| Phone | (858) 369-7100 |
| Web | https://meipharma.com |
MEI Pharma Management Efficiency
The company has return on total asset (ROA) of 0.2004 % which means that it generated a profit of $0.2004 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6168 %, meaning that it created $0.6168 on every $100 dollars invested by stockholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to grow to 0.45. Also, Return On Capital Employed is likely to grow to 0.46. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 11/22/2024, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.Similar Executives
| Found 1 records | CEO Age | ||
| Thomas MBA | Transcode Therapeutics | 72 | |
Management Performance
MEI Pharma Leadership Team
Elected by the shareholders, the MEI Pharma's board of directors comprises two types of representatives: MEI Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MEI. The board's role is to monitor MEI Pharma's management team and ensure that shareholders' interests are well served. MEI Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MEI Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA Esq, COO Counsel | ||
| Anne Frese, Chief Officer | ||
| Eugene Park, VP Marketing | ||
| Virginia Sankey, VP Fin | ||
| JD Esq, Chief Officer | ||
| Eric Deng, VP Operations | ||
| Richard Ghalie, Chief Officer | ||
| MBA MD, Chief Officer | ||
| LLM JD, Senior Affairs | ||
| Robert Mass, Chief Medical Officer | ||
| BA CPA, CFO Sec | ||
| Justin File, CFO Secretary | ||
| Nicole Iida, Vice Affairs | ||
| Daniel Gold, CEO and President and Director | ||
| Yomara GomezNaiden, Senior Quality |
MEI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MEI Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.62 | ||||
| Return On Asset | 0.2 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | (19.29 M) | ||||
| Shares Outstanding | 6.66 M | ||||
| Shares Owned By Insiders | 1.31 % | ||||
| Shares Owned By Institutions | 41.03 % | ||||
| Number Of Shares Shorted | 80.97 K | ||||
| Price To Earning | 30.29 X |
Pair Trading with MEI Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MEI Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MEI Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with MEI Stock
Moving against MEI Stock
| 0.61 | NTRB | Nutriband | PairCorr |
| 0.6 | BMEA | Biomea Fusion | PairCorr |
| 0.58 | VRDN | Viridian Therapeutics | PairCorr |
| 0.44 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.35 | ALVO | Alvotech | PairCorr |
The ability to find closely correlated positions to MEI Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MEI Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MEI Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MEI Pharma to buy it.
The correlation of MEI Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MEI Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MEI Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MEI Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.